ADDISON, Texas, Jan. 17, 2012 /PRNewswire/ --ULURU Inc.
(NYSE AMEX: ULU), announced today that it has extended the
previously announced European license for Altrazeal® to include the
Middle East and North Africa.
Commenting on the extension of the territory, Helmut Kerschbaumer Chairman of Melmed Holdings
AG, stated, "This is a territory where Melmed Holdings AG has
experience marketing to the various sectors in these markets. We
have an extensive network of marketing partners and contacts to
penetrate this market. In addition, there are various European
organizations that provide humanitarian aid to numerous markets
that can be accessed to quickly establish a market presence."
Altrazeal® is a scientifically engineered advanced wound
dressing designed to incorporate the desired features and benefits
of the ideal wound dressings. Altrazeal® competes in the advanced
wound dressing market which worldwide is estimated to be
$6.5 billion growing annually at 13%.
Altrazeal® has demonstrated potential clinical and economic
advantages in a number of chronic and acute wounds including
diabetic foot ulcers, venous ulcers and geriatric wounds.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused
on the development of a portfolio of wound management and oral care
products to provide patients and consumers improved clinical
outcomes through controlled delivery utilizing its innovative
Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery
system. For further information about ULURU Inc., please
visit our website at www.uluruinc.com. For further
information about Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended. These statements are subject to
numerous risks and uncertainties, including but not limited to our
belief that Altrazeal® will be a major competitor in the wound care
market, the ability to quickly establish a market presence, the
cost effectiveness and cost savings of Altrazeal® in healing
chronic wounds, and Altrazeal®'s clinical and economic advantage
and to the risk factors detailed in the Company's Annual Report on
Form 10-K for the year ended December 31,
2010, and other reports filed by us with the Securities and
Exchange Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.